Eigen Therapeutics

Eigen Therapeutics specializes in developing "priming therapies" that upregulate specific antigens in cancer cells to improve the effectiveness of antigen-directed treatments (e.g., ADCs; antibody-drug conjugates). The problem being solved is tumor heterogeneity. Antigen-directed cancer therapies, ADCs and radioligand

Based based in United States, Eigen Therapeutics works in cancer.

Profile

Eigen Therapeutics specializes in developing "priming therapies" that upregulate specific antigens in cancer cells to improve the effectiveness of antigen-directed treatments (e.g., ADCs; antibody-drug conjugates). The problem being solved is tumor heterogeneity. Antigen-directed cancer therapies, ADCs and radioligand therapies (RLTs), sometimes fail in patients due to the heterogeneous expression of the target that they're designed […]

The company sits in the cancer segment, where it competes on its core product or service.

Its base of operations is United States.

The company is listed at the Seed stage of development.

Website: www.eigentx.com